Steven Wijnen, The Netherlands Cancer Institute, Amsterdam, Netherlands, describes a NADINA (NCT04949113) trial analysis linking the CD16a-F158V variant, a germline change that strengthens Fc receptor binding, to poorer prognosis after neoadjuvant ipilimumab plus nivolumab or adjuvant nivolumab in resectable melanoma. Patients carrying the V allele had shorter event-free and distant metastasis-free survival. Tumor transcriptomics revealed heightened natural killer cell and innate immune signaling early in treatment among carriers, implying that antibody-coated CD8+ T cells may be eliminated. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.